

Ref: MLLSEC/106/2026

24 October 2026

To,
BSE Limited,
(Security Code: 540768)
Phiroze Jeejeebhoy Towers,
Dalal Street, Fort,
Mumbai - 400 001

National Stock Exchange of India Ltd.,
(Symbol: MAHLOG)
Exchange Plaza, 5th Floor, Plot No. C/1,
“G” Block, Bandra-Kurla Complex,
Bandra (East), Mumbai – 400 051

Dear Sir/Madam,

Sub: Newspaper Publication of Financial Results – Regulation 47 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“SEBI Listing Regulations”)

Ref: Outcome of Board Meeting vide letter dated 23 October 2026

Please find enclosed extracts of the newspaper publication, in prescribed format, of the Unaudited Consolidated Financial Results for the second quarter and half year ended 30 September 2026, approved by the Board of Directors of the Company at their Meeting held on Friday, 23 October 2026 and published today i.e. on Saturday, 24 October 2026 in Mumbai Edition of the newspapers viz. Business Standard (English) and Sakal (Marathi) (print and electronic version).

The said newspaper publication also includes a Quick Response (QR) Code and the link of webpage to access the financial results for the said period.

This intimation is also being uploaded on the website of the Company and can be accessed at the weblink: <https://mahindralogistics.com/corporate-announcement/newspaper-publications/>

For Mahindra Logistics Limited

JIGNESH
ASHOK PARIKH

Digitally signed by
JIGNESH ASHOK PARIKH
Date: 2026.10.24 13:29:14
+05'30'

Jignesh Parikh
Company Secretary

Enclosure: As above



SIMANDHAR IMPEX LIMITED

CIN : L46498MH2023PLC15552

Registered Office: 811 AWing, Jaswanti Allied Business Cen Ranchandra Lane Extn., Malad West Mumbai City - 400064

Email: simandharimpexlimited@gmail.com Website: www.simandharimpex.com Tel: +91 79798807002

For Simandhar Impex Limited

Sd/-

Amit Suresh Ninawe

Sd/-

Lalit Nagde

EXTRACT OF THE UN-AUDITED STANDALONE FINANCIAL RESULTS FOR THE

QUARTER AND HALF YEAR ENDED ON 30 SEPTEMBER, 2026

(Figures in Lakhs)

S. No.	Particulars	Standalone					
		Quarter Ended		Half Year Ended		Year Ended	
		30-09-2026	30-06-2026	30-09-2025	30-09-2026	30-09-2025	31-03-2026
		(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Un-Audited)	(Audited)
1	Total income from operations (net)	0.00	7.63	0.00	7.63	0.00	154.40
2	Net Profit/ (Loss) from the period (before Tax, Exceptional and/or Extraordinary Items)	-10.67	-6.56	-0.24	-17.23	-0.47	1.33
3	Net Profit/ (Loss) for the period before tax (after Exceptional and/or Extraordinary Items)	-10.67	-6.56	-0.24	-17.23	-0.47	0.58
4	Net Profit/(Loss) for the period after tax (after Exceptional and/or Extraordinary Items)	-10.67	-6.56	-0.24	-17.23	-0.47	0.58
5	Total Comprehensive Income for the period (Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax))	0.00	0.00	0.00	0.00	0.00	0.00
6	Paid up Equity Share Capital (Face Value of Rs. 10 each fully paid up)	305.69	305.69	1.00	305.69	1.00	305.69
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	-	-	-	-	-	20.82
8	Earnings per share (of Rs.10/- each) (not annualised) (for continuing and discontinued operations) -						
	- Basic	-0.03	-0.02	-0.24	-0.06	-0.47	0.00
	- Diluted	-0.03	-0.02	-0.24	-0.06	-0.47	0.00

Notes :

1 The above is an extract of the detailed format of Quarterly Unaudited Financial Results for the quarter and half year ended ended September 30, 2026 filed with the Stock Exchange under Regulation 33 of the SEBI (Listing and Other Disclosure Requirements) Regulations, 2015. The full format of the Quarter ended Standalone Unaudited Financial Results are available on the website of the Company <https://simandharimpex.com/wp-content/uploads/2026/10/Regulation-30-Result-of-2nd-Qt-30-09-2026-.pdf>) and on the website of Stock Exchange where the share of the of the Company are listed at BSE Limited (www.bseindia.com)

2 The above results for the quarter and half year ended September 30, 2026 have been reviewed by the Audit Committee and approved by the Board of Directors of the Company at their respective meetings held on October 23, 2026. The Statutory Auditors of the Company have carried out a Limited Review of the aforesaid financial results and issued their Limited Review Report thereon.



Place: Mumbai

Date : 23.10.2026

For Simandhar Impex Limited

Sd/-

Amit Suresh Ninawe

Sd/-

Lalit Nagde

PUBLIC NOTICE

REDUCTION IN MAXIMUM RETAIL PRICE (MRP) OF ANTI-CANCER MEDICINES

RPG LIFE SCIENCE LIMITED

Regd. Off.: RPG House, 463, Dr. Annie Besant Road, Worli, Mumbai - 400030

Tel: +91-2224981650 / 66606375, Fax: +91-2224970127

Email: info@rpglifesciences.com, www.rpglifesciences.com

CIN: L24232MH2007PLC169354

In compliance with Order **S.O. 5690(E)** dated **17th October 2026** issued by the National Pharmaceutical Pricing Authority (NPPA), Department of Pharmaceuticals, Government of India, under Paragraph 19 of the Drugs (Prices Control) Order, 2013, the trade margin on specified non-scheduled anti-cancer medicines has been capped at 30%.

Accordingly, **RPG LIFE SCIENCES LTD.** has reduced the MRP of the following products. **The revised MRPs will be effective from 9th November 2026.**

Sl. No.	Brand Name	Drug	Strength & Dosage Form	Pack Size	Current MRP (incl. of GST) (Rs.)	Revised MRP (incl. of GST) (Rs.) Effective from 9th November 2026
1	Abitate 250 mg Tablet	Abiraterone acetate	250mg (Tablet)	120 Nos	25,883.24	5,261.00
2	Abitate 500mg	Abiraterone acetate	500mg (Tablet)	60 Nos	25,500.00	5,249.00
3	Abitate U 250mg	Abiraterone acetate	250mg (Tablet)	120 Nos	37,417.36	6,278.00
4	Abitate U 500mg	Abiraterone acetate	500mg (Tablet)	60 Nos	25,500.00	5,246.00
5	ACALBRIGHT 100mg	Acalabrutinib	100mg (Capsule)	30 Nos	17,999.00	7,962.00
6	ANARZOLE	Anastrozole	1mg (Tablet)	10 Nos	695.76	73.00
7	ARPRIDE 150mg	Olaparib	150mg (Tablet)	60 Nos	19,500.00	11,999.00
8	AZAPLAST 100MG INJ	Azacitidine	100mg (Injection)	1 Vial	5,088.14	1,279.00
9	Debrumab 60 mg	Denosumab	60mg (Injection)	1ml pfs	22,031.25	5,941.00
10	Denbri	Denosumab	60mg (Injection)	1ml pfs	29,312.60	7,239.00
11	Densurank 60 mg	Denosumab	60mg (Injection)	1ml pfs	29,315.62	7,568.00
12	Enuta	Enzalutamide	40mg (Capsule)	28 Nos	6,578.20	2,232.00
13	ENUITA 160MG 7's	Enzalutamide	160mg (Capsule)	7 Nos	6,578.20	3,725.00
14	EnzaMate 160mg	Enzalutamide	160mg (Tablet)	7 Nos	6,578.20	3,134.00
15	Enzamate 40 mg	Enzalutamide	40mg (Tablet)	7 Nos	6,578.20	2,212.00
16	Erubin 50 mg Inj 1's	Epirubicin	50mg (Injection)	1 Vial	960.63	629.00
17	Fulbreca 1's	Fulvestrant	50mg (Injection)	5ml Vial	26,072.16	5,491.00
18	Ivzumab 100 mg	Bevacizumab	100mg (Injection)	1 Vial	26,621.75	4,493.00
19	Ivzumab 400 mg	Bevacizumab	400mg (Injection)	1 Vial	69,852.12	13,512.00
20	Palbopro	Palbociclib	125mg (Capsule)	21 Nos	40,421.33	2,720.00
21	Peg Frastim	Pegfilgrastim	6mg (Injection)	1ml pfs	6,660.85	1,807.00
22	PEMEXAR 100 MG	Pemetrexed	100mg (Injection)	1 Vial	1,892.98	468.00
23	PEMEXAR 500 MG	Pemetrexed	500mg (Injection)	1 Vial	7,050.56	1,219.00

Ashok Nair

Managing Director
RPG Life Sciences Ltd.

Date: 24/10/2026

Place: Mumbai

MAHINDRA LOGISTICS MAHINDRA LOGISTICS LIMITED Registered Office: Mahindra Towers, P. K. Kurne Chowk, Worli, Mumbai - 400 018. Website: www.mahindralogistics.com • E-mail: cfo.ml@mahindralogistics.com • Phone: +91 22 2490 1441 • CIN: L63000MH2007PLC173466 EXTRACT OF CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND HALF YEAR ENDED 30 SEPTEMBER 2026			
			Rs. In Crores
S.No.	Particulars	Quarter Ended	Half Year Ended
		30-Sep-26	30-Sep-26
		Unaudited	Unaudited
1	Total Income from Operations	2,095.43	4,098.31
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items)	40.30	79.36
3	Net Profit/(Loss) for the period before Tax (after Exceptional and/or Extraordinary items)	40.30	79.36
4	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary items but before share of loss of Joint venture/Associate)	28.93	56.81
5	Net Profit/(Loss) for the period after Tax (after Exceptional and/or Extraordinary items and after share of loss of Joint venture/Associate)	28.87	56.70
	Attributable to Shareholders of the company	26.25	51.64
	Attributable to Non-Controlling Interests	2.62	5.06
6	Total Comprehensive Income/(Losses) for the period [Comprising Profit/(Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	26.18	51.50
	Attributable to Shareholders of the Company	2.62	5.06
	Attributable to Non-Controlling Interests	99.28	99.28
7	Equity Share Capital (Face value Rs 10/- per share)		1,075.56
8	Reserves (excluding revaluation reserve) as shown in the audited balance sheet of the previous year		
a.	Earnings per share (Face value Rs 10/- per share)		
b.	Basic Earnings per share (Rs.)	2.64	5.20
c.	Diluted Earnings per share (Rs.)	2.64	5.19

Notes

- The Unaudited Consolidated Financial Results have been reviewed and recommended by the Audit Committee and approved by the Board of Directors at their respective Meetings held on 23 October 2026. The statutory auditors have performed limited review of the financial results.
- The Unaudited Consolidated Financial Results have been prepared and published in accordance with the Indian Accounting Standards, Section 133 of the Companies Act, 2013 read with Rules framed thereunder and Regulation 33 of SEBI Listing Regulations, as amended from time to time.
- The Company has consolidated the financial results of its subsidiaries and Joint Venture as per the applicable Indian Accounting Standards.
- The Board of Directors had recommended final dividend of ₹ 2.50 per equity share for the year ended 31 March 2026 at its meeting held on 23 April 2026 which has been approved by the Shareholders at the 19th Annual General Meeting held on 20 July 2026. The aforesaid dividend was paid during the quarter ended 30 September 2026 and resulted in outflow of ₹ 24.81 crores.
- During the quarter ended 30 September 2026, the Company has allotted 54,919 equity shares of Rs. 10 each fully-paid-up, on exercise of Restricted Stock Units (RSUs) by eligible employees under the Mahindra Logistics Employee Restricted Stock Unit Plan 2018.
- Standalone Financial Results for the period:

				Rs. in Crores
Particulars		Quarter Ended	Half Year Ended	Quarter Ended
		30-Sep-26	30-Sep-26	30-Sep-25
		Unaudited	Unaudited	Unaudited
Total Income from Operations		1,713.75	3,368.64	1,366.91
Profit before tax		46.84	85.62	5.12
Profit after tax		37.63	66.63	3.79
Total comprehensive income		37.56	66.49	3.72

- The above is an extract of the detailed format of the said Financial Results for the quarter and half year ended 30 September 2026 filed with the Stock Exchanges under Regulation 33 of the SEBI Listing Regulations. The full format of the said Financial Results are available on the Company's website viz. www.mahindralogistics.com and on the Stock Exchange websites - BSE Limited (www.bseindia.com) and National Stock Exchange of India Limited (www.nseindia.com).

For Mahindra Logistics Limited

Hemant Sikka
Managing Director & CEO
DIN: 00922281

Place : Mumbai
Date: 23 October 2026

